Published in Cancer Weekly, August 5th, 2003
This study - presented in part at a plenary session at last year's meeting of the American Society for Clinical Oncology (ASCO) - is the first to show a benefit for this type of cancer.
"For the first time we have a therapy for mesothelioma that makes a difference," said study director Nicholas J. Vogelzang, MD, Fred C. Buffett Professor of Medicine and director of the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.